Ariad Pharmaceuticals Inc., of Cambridge, Mass., reported data on brigatinib, its anaplastic lymphoma kinase (ALK) inhibitor, from the pivotal ALTA trial in ALK-positive non-small cell lung cancer patients who experienced disease progression on crizotinib (Xalkori, Pfizer Inc.).